Company intelligence / Profile preview

Biomendex

Tampere, Pirkanmaa, Finlandbiomendex.com ↗

Ownership: Private
Development stage: Commercial

Overview

Biomendex has developed Adaptos®, a fully synthetic and biodegradable adaptive bone graft substitute designed to mimic cancellous bone. The company’s first clinical study in humans focuses on orthopedic applications such as high tibial osteotomy. Early veterinary results are positive with successful surgeries in small animals. Human clinical testing began in spring 2020 for dental applications, with broader orthopedic studies ongoing[1][5][6].

Therapeutic areas: OtherNeurology
Modalities: Device
Industry: Surgical Medical Devices

Drug pipeline

1 asset

Adaptos

Commercial

Indications: Veterinary bone defects, Orthopedic injuries

Partnerships

Mayo Clinic collaboration to advance Adaptos® for new indications and FDA approval[2]

Beyond the preview

Go deeper on Biomendex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biomendex.

Explore the full profile